论文部分内容阅读
目的观察拉米夫定用于乙型肝炎失代偿期肝硬化患者抗病毒治疗的疗效。方法将61例乙型肝炎失代偿期肝硬化患者随机分为两组。治疗组31例,对照组30例。两组均采用常规内科综合治疗,治疗组加用拉米夫定100 mg/d口服,疗程1年。结果治疗组在1年治疗结束时肝功能恢复情况及HBV-DNA转阴率均优于对照组(P<0.01)。结论拉米夫定抗病毒治疗能明显改善失代偿期肝硬化患者的肝功能及预后。
Objective To observe the efficacy of lamivudine for antiviral treatment of patients with decompensated cirrhosis of the liver. Methods Sixty-one patients with decompensated cirrhosis of liver were randomly divided into two groups. 31 cases in the treatment group and 30 cases in the control group. Both groups were treated by conventional internal medicine. The treatment group was given lamivudine 100 mg / d orally for 1 year. Results The recovery of liver function and the negative rate of HBV DNA in the treatment group were better than those in the control group at the end of one year (P <0.01). Conclusion Lamivudine antiviral therapy can significantly improve the liver function and prognosis of patients with decompensated cirrhosis.